Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway
- 12 November 2015
- journal article
- laboratory investigation
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 126 (3) , 397-404
Abstract
Glioblastoma (GBM) is the most common primary tumor of the CNS and carries a dismal prognosis. The aggressive invasion of GBM cells into the surrounding normal brain makes complete resection impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to 8 months for patients with recurrent GBM. New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome. We have demonstrated that TROY (TNFRSF19), a member of the TNFR super-family, plays an important role in GBM invasion and resistance. Knockdown of TROY expression inhibits GBM cell invasion, increases sensitivity to temozolomide, and prolongs survival in an intracranial xenograft model. Propentofylline (PPF), an atypical synthetic methylxanthine compound, has been extensively studied in Phase II and Phase III clinical trials for Alzheimer’s disease and vascular dementia where it has demonstrated blood–brain permeability and minimal adverse side effects. Here we showed that PPF decreased GBM cell expression of TROY, inhibited glioma cell invasion, and sensitized GBM cells to TMZ. Mechanistically, PPF decreased glioma cell invasion by modulating TROY expression and downstream signaling, including AKT, NF-κB, and Rac1 activation. Thus, PPF may provide a pharmacologic approach to target TROY, inhibit cell invasion, and reduce therapeutic resistance in GBM.Keywords
Funding Information
- National Cancer Institute (P50 CA108961)
- National Institute of Neurological Disorders and Stroke (NS086853)
- Ben and Catherine Ivy Foundation
This publication has 33 references indexed in Scilit:
- TROY (TNFRSF19) Promotes Glioblastoma Survival Signaling and Therapeutic ResistanceMolecular Cancer Research, 2013
- Propentofylline Targets TROY, a Novel Microglial Signaling PathwayPLOS ONE, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microgliaNeuro-Oncology, 2011
- TROY (TNFRSF19) Is Overexpressed in Advanced Glial Tumors and Promotes Glioblastoma Cell Invasion via Pyk2-Rac1 SignalingMolecular Cancer Research, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic targetInternational Journal of Cancer, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing olfactory systemGlia, 2004
- Characterization of TNFRSF19, a Novel Member of the Tumor Necrosis Factor Receptor SuperfamilyGenomics, 1999